Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ABBLO PHARMA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   0.0% 7.6% 8.0% 6.9% 5.4% 8.3% 16.2% 16.0%   Credit score (0-100)   0 33 31 33 41 29 11 12   Credit rating   N/A BB BB BBB BBB BB BB BB   Credit limit (kDKK)   -112.7 -0.0 -0.0 -0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   146 306 376 740 1,056 806 0.0 0.0   EBITDA   58.6 152 253 316 358 180 0.0 0.0   EBIT   58.6 152 253 316 358 180 0.0 0.0   Pre-tax profit (PTP)   12.1 100.5 213.8 285.2 300.8 107.4 0.0 0.0   Net earnings   12.1 100.5 213.8 285.2 300.8 107.4 0.0 0.0   Pre-tax profit without non-rec. items   12.1 100 214 285 301 107 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -1,229 -1,128 -914 -629 -328 -221 -301 -301   Interest-bearing liabilities   1,495 1,324 1,008 934 923 889 301 301   Balance sheet total (assets)   576 516 764 882 1,162 1,499 0.0 0.0   Net Debt   1,376 1,156 807 748 711 259 301 301     See the entire balance sheet 1000.0 Volume  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   146 306 376 740 1,056 806 0.0 0.0   Gross profit growth   21.3% 110.5% 22.6% 97.1% 42.6% -23.7% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   576 516 764 882 1,162 1,499 0 0   Balance sheet change%   2.9% -10.4% 48.1% 15.5% 31.7% 29.0% -100.0% 0.0%   Added value   58.6 151.9 252.8 315.5 357.6 180.4 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   40.3% 49.6% 67.3% 42.6% 33.9% 22.4% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   3.6% 8.9% 15.3% 21.0% 25.1% 12.1% 0.0% 0.0%   ROI %   4.4% 10.9% 21.8% 34.5% 40.6% 21.5% 0.0% 0.0%   ROE %   2.1% 18.4% 33.4% 34.7% 29.4% 8.1% 0.0% 0.0%   1000.0 Solidity  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -68.1% -68.6% -54.5% -41.6% -22.0% -12.9% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   2,347.6% 760.9% 319.2% 236.9% 198.9% 143.8% 0.0% 0.0%   Gearing %   -121.7% -117.3% -110.3% -148.4% -281.0% -402.3% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   4.0% 3.7% 3.4% 5.2% 8.2% 9.6% 0.0% 0.0%   1000.0 Liquidity  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.0 1.0 0.7 0.9 1.2 1.5 0.0 0.0   Current Ratio   1.9 1.6 1.1 1.5 2.0 1.8 0.0 0.0   Cash and cash equivalent   118.8 168.2 201.2 186.3 211.7 629.8 0.0 0.0   1000.0 Capital use efficiency  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   266.5 195.7 93.7 304.7 594.6 668.1 -150.5 -150.5   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 N/A 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   59 152 253 316 358 180 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   59 152 253 316 358 180 0 0   EBIT / employee   59 152 253 316 358 180 0 0   Net earnings / employee   12 100 214 285 301 107 0 0